BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

This multi-center, randomized, double-blind, placebo-controlled study will evalu ate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma at high risk for recurrence. Patient s will be randomized to receive oral doses of vemurafenib 960 mg twice daily or matching placebo. The anticipated time on study treatment is 52 weeks.

Principal Investigator

Stanford Investigator(s)


Primary Contact:
Jennifer Vargas
(650) 723-0371